Vincent D.

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the worlds first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Tuspark Capital Management is a Luxembourg subsidiary of Tus-Holdings, incorporated as the General Partner (GP) of a Luxembourg based PE/VC fund CLLIF. Tus-Holdings was originated from the former Tsinghua University Science Park (TusPark), the largest University Park in the world. Tus-holdings is the controlling shareholder or shareholder of a number listed public companies and more than 300 private companies with total assets over 15 billion US dollars, largely in high-tech and innovative businesses. Our group has invested and operates over 30 science parks including TUSPARK HQs and TUSPARK Cambridge and 160 incubators hosting more than 5000 start-ups in China and overseas to promote innovation. We inherits the capability of a full supply-chain incubation established by Tus-Holdings with the model of “incubation + investment + M&As”. All these parks/incubators, investment funds, corporates and their subsidiaries in China and abroad form an integrated TUS network. In Europe, we invest in growth companies and innovative businesses in environment, new energies and new materials, high-end manufacturing, life science and med-tech, AI, digital and fintech industries through our Luxembourg fund CLIIF and co-investments with other TUS funds from China and overseas.

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the worlds first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

Robocath is a french medtech which designs, develops and commercializes robotic solutions to treat cardiovascular diseases. R-One™ is the first european robotic-assisted solution for PCI. The company obtained the CE-mark for R-One™ in February 2019. It is designed to operate with precision and perform specific movements creating better interventional conditions (radioprotection). Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs. Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. We are convinced that the future standard for minimally-invasive procedures is robot-based.